Design of experiments

Global Alopecia Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

The "Global Alopecia Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Alopecia Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Alopecia Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Alopecia market.
  • It covers emerging therapies for Alopecia in active clinical development stages including early and late stage clinical trials.
  • The report provides Alopecia pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Uveitis Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

The "Global Uveitis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Uveitis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Uveitis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Uveitis market.
  • It covers emerging therapies for Uveitis in active clinical development stages including early and late stage clinical trials.
  • The report provides Uveitis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Endometriosis Clinical Trial Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

The "Global Endometriosis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Endometriosis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Endometriosis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Endometriosis market.
  • It covers emerging therapies for Endometriosis in active clinical development stages including early and late stage clinical trials.
  • The report provides Endometriosis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC)

Retrieved on: 
Wednesday, July 21, 2021

STOCKHOLM, July 21, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer's Association International Conference (AAIC) to be held in Denver, Colorado and virtually from July 26 to 30, 2021. The presentations will include the latest data of the investigational anti-amyloid beta (Aβ) protofibril selective antibody lecanemab (BAN2401) for which the FDA has granted Breakthrough Therapy designation.

Key Points: 
  • Baseline Characteristics for Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab (BAN2401)
    This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety.
  • There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
  • Oskar Bosson, Vice President Communications and Investor Relations, BioArctic AB

Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC)

Retrieved on: 
Wednesday, July 21, 2021

STOCKHOLM, July 21, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer's Association International Conference (AAIC) to be held in Denver, Colorado and virtually from July 26 to 30, 2021. The presentations will include the latest data of the investigational anti-amyloid beta (Aβ) protofibril selective antibody lecanemab (BAN2401) for which the FDA has granted Breakthrough Therapy designation.

Key Points: 
  • Baseline Characteristics for Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab (BAN2401)
    This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety.
  • There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
  • Oskar Bosson, Vice President Communications and Investor Relations, BioArctic AB

Lumos Pharma Announces Clinical Updates

Retrieved on: 
Tuesday, July 20, 2021

AUSTIN, Texas, July 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announces an update on clinical activities.

Key Points: 
  • TheFDA has placed our planned long-term extension study on partial clinical hold until additional efficacy data from the OraGrowtH210 Trial are available to be reviewed.
  • We do not anticipate these protocol changes, on a stand-alone basis, to extend the time to the initiation of our Phase 3 clinical trial.
  • Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases.
  • This press release contains forward-looking statements of Lumos Pharma, Inc. (the Company) that involve substantial risks and uncertainties.

Medable Named Leader in Decentralized Clinical Trial Products Assessment by Everest Group

Retrieved on: 
Tuesday, July 20, 2021

Medable Inc. , the leading cloud platform for patient-centered drug development, today announced that it was named a Leader in the Decentralized Clinical Trial Products PEAK Matrix assessment by Everest Group.

Key Points: 
  • Medable Inc. , the leading cloud platform for patient-centered drug development, today announced that it was named a Leader in the Decentralized Clinical Trial Products PEAK Matrix assessment by Everest Group.
  • The new report, issued last Friday, evaluates decentralized trial products from 15 companies based on vision, capability and market impact.
  • Medable has emerged as a leader in the industry shift to decentralized clinical trials, making trials accessible for everyone everywhere and enabling effective therapies to reach patients faster.
  • Medable has deployed its software-as-a-service (SaaS) platform in more than 60 countries via more than 150 decentralized and hybrid clinical trials.

THREAD Recognized for Frost & Sullivan’s 2021 Customer Value Leadership Award

Retrieved on: 
Tuesday, July 20, 2021

THREAD , a leading technology and service provider enabling decentralized clinical trials (DCTs), announced today that it has been awarded Frost & Sullivans 2021 Customer Value Leadership Award in the decentralized clinical trials industry.

Key Points: 
  • THREAD , a leading technology and service provider enabling decentralized clinical trials (DCTs), announced today that it has been awarded Frost & Sullivans 2021 Customer Value Leadership Award in the decentralized clinical trials industry.
  • Frost & Sullivans global team of analysts independently evaluated criteria across the areas of business and customer impact to determine award recipients.
  • We are thrilled with this recognition from Frost & Sullivan for our advancements in the planning and execution of decentralized clinical trials.
  • For more information on the Frost & Sullivan 2021 Customer Value Leadership Award, click here .

ISA Pharmaceuticals, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline

Retrieved on: 
Tuesday, July 20, 2021

The clinical study, to be conducted in close collaboration with the Gastroenterology & Hepatology department of the Erasmus MC, is entitled the 'HEB-PEP study'.

Key Points: 
  • The clinical study, to be conducted in close collaboration with the Gastroenterology & Hepatology department of the Erasmus MC, is entitled the 'HEB-PEP study'.
  • The project starts in August 2021 and the clinical phase is expected to begin in 2022.
  • It will provide an insight into which dose of ISA104 is safe, tolerable and potentially effective in chronic HBV patients.
  • It will be ISA's next program to go into clinical development, with its lead program ISA101b in late-stage clinical trials for human papillomavirus type 16 (HPV16) induced cancers.

SA Pharmaceuticals, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline

Retrieved on: 
Tuesday, July 20, 2021

The clinical study, to be conducted in close collaboration with the Gastroenterology & Hepatology department of the Erasmus MC, is entitled the 'HEB-PEP study'.

Key Points: 
  • The clinical study, to be conducted in close collaboration with the Gastroenterology & Hepatology department of the Erasmus MC, is entitled the 'HEB-PEP study'.
  • The project starts in August 2021 and the clinical phase is expected to begin in 2022.
  • It will provide an insight into which dose of ISA104 is safe, tolerable and potentially effective in chronic HBV patients.
  • It will be ISA's next program to go into clinical development, with its lead program ISA101b in late-stage clinical trials for human papillomavirus type 16 (HPV16) induced cancers.